Earnings Call Insights: Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Management View Chad Robins, Co-Founder, CEO & Chairman, highlighted "2025 was a remarkable year for Adaptive, marked by strong execution and meaningful progress across the business." Robins reported full-year MRD revenue growth of 46% year-over-year and noted the company achieved profitability ahead of expectations. He an...
Earnings Call Insights: Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Management View Chad Robins, Co-Founder, CEO & Chairman, highlighted "2025 was a remarkable year for Adaptive, marked by strong execution and meaningful progress across the business." Robins reported full-year MRD revenue growth of 46% year-over-year and noted the company achieved profitability ahead of expectations. He announced several catalysts for sustained growth, including accelerated EMR integrations, the launch of NovaSeq X Plus, Medicare coverage for recurrence monitoring in MCL, updates in NCCN guidelines, and strong data generation with over 90 abstracts presented at ASH. Robins stated the Immune Medicine business scaled TCR-antigen data and modeling capabilities, leading to two data partnerships, and completed a preclinical data package for the lead TCR depleting antibody program in ankylosing spondylitis. He explained, "Taken together, the strong MRD execution, the continued progress in Immune Medicine and the disciplined spending across the organization drove 55% total company revenue growth and a 68% reduction in cash burn, leading to a strong cash balance of $227 million at year-end." Kyle Piskel, VP, CFO & Principal Accounting Officer, reported "Total company revenue for the fourth quarter was $71.7 million and for the full year was $277 million, representing 51% and 55% year-over-year growth, respectively." Piskel added, "Total company adjusted EBITDA was $4.1 million in the fourth quarter compared to a loss of $16.4 million a year ago. For the full year, adjusted EBITDA was $12.2 million compared to a loss of $80.4 million in 2024." Outlook Management expects clonoSEQ test volumes to grow by more than 30% year-over-year in 2026, driven by a shift towards blood-based testing, deeper community penetration, expanded EMR integration, and ongoing data generation. The company is targeting an average ASP of approximately $1,400 per test in 2026 and plans to increase the number of...
Earnings Call Insights: Newell Brands Inc. (NWL) Q4 2025 Management View CEO Christopher Peterson highlighted that "2025 proved more difficult than we anticipated at the start of the year" due to unexpected tariff interventions, which required "multiple pricing actions, which significantly affected consumer behavior and retail dynamics." Despite these challenges, Peterson reported that "the team a...
Earnings Call Insights: Newell Brands Inc. (NWL) Q4 2025 Management View CEO Christopher Peterson highlighted that "2025 proved more difficult than we anticipated at the start of the year" due to unexpected tariff interventions, which required "multiple pricing actions, which significantly affected consumer behavior and retail dynamics." Despite these challenges, Peterson reported that "the team acted decisively across sourcing, productivity, domestic manufacturing and pricing in response to these challenges," including reducing China sourcing exposure to below 10% and launching a global productivity plan supported by automation, digitization, and AI. Peterson emphasized continued investment in domestic manufacturing, noting "roughly $40 million of incremental tariff advantaged business wins in the second half of 2025" and expansion of normalized operating margin for the year while increasing advertising and promotional support by 50 basis points. The Learning and Development segment was described as "the most resilient segment across the portfolio this past year," with Writing brands like Sharpie and EXPO seeing improved distribution and innovation-driven growth. The Baby business reported "a 160 basis point increase in market share" for the full year, and "in the fourth quarter, Graco's market share was up over 350 basis points." Peterson outlined that for 2026, "our guidance assumes that the categories we participate in will decline by approximately 2% for the year," but stated confidence to outperform categories and grow market share for the first time since the Jarden acquisition, supported by "more than 25 Tier 1 or 2 launches planned for 2026." CFO Mark Erceg stated, "Fourth quarter net sales were $1.9 billion, down 2.7% versus last year, and core sales declined 4.1%... fourth quarter core sales exceeded our revised expectations." He added, "Normalized gross margin 33.9% 70 basis points versus last year... normalized fourth quarter gross margin was up 730 bas...
Earnings Call Insights: Canopy Growth Corporation (WEED:CA) Q3 2026 Management View CEO Luc Mongeau stated that "Q3 was a quarter where Canopy Growth delivered significant progress on multiple levels, and it reinforced my confidence that we're building stronger business." He highlighted a net cash position of $146 million and $371 million in cash and cash equivalents, as well as a post-quarter $15...
Earnings Call Insights: Canopy Growth Corporation (WEED:CA) Q3 2026 Management View CEO Luc Mongeau stated that "Q3 was a quarter where Canopy Growth delivered significant progress on multiple levels, and it reinforced my confidence that we're building stronger business." He highlighted a net cash position of $146 million and $371 million in cash and cash equivalents, as well as a post-quarter $150 million USD recapitalization extending all debt maturities to 2031. Mongeau described this as providing "more flexibility around near-term financing, including how and when we use tools like the ATM and more room to make the right long-term decisions." The CEO emphasized the proposed acquisition of MTL Cannabis, calling it "accretive," with MTL "bring[ing] a profitable, cash-generating business" and enhancing Canopy's capabilities in high-quality flower and operational discipline. He noted that MTL will strengthen Canopy's leadership in Canadian medical cannabis, expand its Quebec presence, and fuel growth both domestically and internationally. Mongeau reported "the slimmest adjusted EBITDA loss to date, driven by continued cost discipline and improving execution across our Canadian medical and adult-use channels." Canadian medical net revenue grew 15% year-over-year, marking six consecutive quarters of growth, while Canadian adult-use net revenue increased 8% year-over-year. International business saw a 22% sequential increase in net revenue. For Storz & Bickel, Mongeau said net revenue grew 45% sequentially, with the VEAZY vaporizer driving strategy around affordability and portability. He also mentioned continued strategic optionality via Canopy USA amid regulatory evolution. CFO Thomas Stewart stated, "With our aggressive cost-saving actions taken to date, we have been able to identify and capture $29 million of annualized savings, far exceeding our initial expectations. This, coupled with the growth we are witnessing in the Canadian business, gives us the confidence ...
Astera Labs Inc.’s stocks have been trading up by 16.5 percent, signaling strong investor optimism amid strategic innovations. Key Takeaways Recent reports suggest strong financial performance for ALAB, with increases in revenue and profitability marking a positive outlook. Expanded market reach and strategic partnerships have contributed to ALAB’s recent share price uptick. Analysts praise ALAB’s...
Astera Labs Inc.’s stocks have been trading up by 16.5 percent, signaling strong investor optimism amid strategic innovations. Key Takeaways Recent reports suggest strong financial performance for ALAB, with increases in revenue and profitability marking a positive outlook. Expanded market reach and strategic partnerships have contributed to ALAB’s recent share price uptick. Analysts praise ALAB’s ability to leverage investments effectively, pushing the stock to new heights. ALAB’s innovative strategies gain traction, reflecting growing investor confidence in the company’s future growth. Broader market conditions and tech sector trends align to boost ALAB’s valuation and appeal. Live Update At 12:12:59 EST: On Friday, February 06, 2026 Astera Labs Inc. stock [NASDAQ: ALAB] is trending up by 16.5%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below. Quick Financial Overview Astera Labs Inc. has reported a promising financial outlook this quarter, emphasizing not only an increase in revenue but revenue per share as well. Revenue stood at $396.29M, with a gross margin of 75.4%. Such strong performance underscores the company’s potential in the tech sector. Key profitability indicators remain favorable, with an EBIT margin of 19.2% and a profit margin of 27.5%. More Breaking News With a current enterprise value nearing $22.98B, the company has managed significant financial leverage, reflected in a price-to-sales ratio of 37.03. The PE ratio, albeit high at 72.05, suggests robust growth expectations. ALAB’s focus on strategic growth and market expansion plays a role in improving its asset turnover and receivables turnover, yielding sustainable returns for its investors. Market Reactions and Thematic Overview The recent sprint in ALAB’s stock price captivates investors as the journey foretold by financial analysts begins to materialize. With the technology sector on an ascent, ALAB’s strategic partnerships and mark...
AGC Inc. press release ( ASGLY ): FY GAAP EPS of ¥325.67. Revenue of ¥2058.8B (-0.4% Y/Y). More on AGC Inc. AGC Inc. (ASGLY) Q4 2025 Earnings Call Transcript AGC Inc. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on AGC Inc. Historical earnings data for AGC Inc. Financial information for AGC Inc.
AGC Inc. press release ( ASGLY ): FY GAAP EPS of ¥325.67. Revenue of ¥2058.8B (-0.4% Y/Y). More on AGC Inc. AGC Inc. (ASGLY) Q4 2025 Earnings Call Transcript AGC Inc. 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on AGC Inc. Historical earnings data for AGC Inc. Financial information for AGC Inc.
Chinmayi Shroff Shares of SpyGlass Pharma ( SGP ) and Agomab Therapeutics ( AGMB ) are expected to begin trading on Nasdaq on Friday after the clinical-stage biotechs priced their offerings, indicating a combined $350M in gross proceeds. SpyGlass ( SGP ), an ophthalmology-focused drug delivery company, priced its initial public offering of 9.375M shares at $16.00 apiece on Thursday, seeking to rai...
Chinmayi Shroff Shares of SpyGlass Pharma ( SGP ) and Agomab Therapeutics ( AGMB ) are expected to begin trading on Nasdaq on Friday after the clinical-stage biotechs priced their offerings, indicating a combined $350M in gross proceeds. SpyGlass ( SGP ), an ophthalmology-focused drug delivery company, priced its initial public offering of 9.375M shares at $16.00 apiece on Thursday, seeking to raise roughly $150M in gross proceeds. The California-based biotech intends to use the proceeds to fund studies for its lead candidate, the Bimatoprost Drug Pad-IOL System, which is undergoing two phase 3 trials for open-angle glaucoma and ocular hypertension, with data expected in 2027. Meanwhile, Belgian biotech AgomAb Therapeutics ( AGMB ) eyes $200M in gross proceeds from its offering of 12.5M American Depositary Shares, which it priced at $16.00 apiece on Thursday. The Antwerp-based company’s pipeline is led by ontunisertib, a small-molecule drug targeting an inflammatory bowel disorder called fibrostenosing Crohn’s disease. AgomAb's near-term catalysts include the initiation of a Phase 2b trial for ontunisertib in patients with symptomatic FSCD in H2 2026. More on AgomAb Therapeutics NV, SpyGlass Pharma, Inc. AgomAb Therapeutics NV Readies US IPO On Early Promising Results SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates Belgian biopharma Agomab to raise up to $210M in U.S. IPO Seeking Alpha’s Quant Rating on AgomAb Therapeutics NV Financial information for AgomAb Therapeutics NV
The dollar index (DXY00) today is down by -0.17%. Today’s rebound in equity markets has reduced liquidity demand for the dollar. The dollar is also being pressured by some negative carryover from Thursday, when weaker-than-expected US labormarket newsboosted the chance of a Fed rate cut at next month’s FOMC meeting to 18% from 8% on Wednesday. Losses in the dollar are limited after the University ...
The dollar index (DXY00) today is down by -0.17%. Today’s rebound in equity markets has reduced liquidity demand for the dollar. The dollar is also being pressured by some negative carryover from Thursday, when weaker-than-expected US labormarket newsboosted the chance of a Fed rate cut at next month’s FOMC meeting to 18% from 8% on Wednesday. Losses in the dollar are limited after the University of Michigan US Feb consumer sentiment index unexpectedly rose to a 6-month high. The dollar sank to a 4-year low last Tuesday when President Trump said he’s comfortable with the recent weakness in the dollar. Also, the dollar remains under pressure as foreign investors pull capital from the US amid a growing budget deficit, fiscal profligacy, and widening political polarization. Join 200K+ Subscribers: The University of Michigan US Feb consumer sentiment index unexpectedly rose +0.9 to a 6-month high of 57.3, stronger than expectations of a decline to 55.0. The University of Michigan US Feb 1-year inflation expectations fell to a 13-month low of 3.5%, weaker than expectations of no change at 4.0%. The Feb 5-10 year inflation expectations ticked up to 3.4%, stronger than expectations of no change at 3.3%. Hawkish comments today from Atlanta Fed President Raphael Bostic were supportive of the dollar when he said, “It’s paramount for the Fed to keep monetary policy in a restrictive posture so that we get inflation back to 2%.” Swaps markets are discounting the odds at 18% for a -25 bp rate cut at the next policy meeting on March 17-18. The dollar continues to see underlying weakness as the FOMC is expected to cut interest rates by about -50 bp in 2026, while the BOJ is expected to raise rates by another +25 bp in 2026, and the ECB is expected to leave rates unchanged in 2026. EUR/USD (^EURUSD) recovered from a 2-week low today and is up by +0.28%. The euro initially moved lower today after German Dec industrial production fell more than expected. However, the euro recovered it...
This article first appeared on GuruFocus. Wall Street bounced on Friday, with investors returning to technology stocks after assessing the impact of artificial intelligence on the software sector. The Dow Jones Industrial Average climbed 918 points, or about 2%, led by industrial stocks like Caterpillar (NYSE:CAT) and financial firms such as Goldman Sachs (NYSE:GS). The S&P 500 rose 1%, while the ...
This article first appeared on GuruFocus. Wall Street bounced on Friday, with investors returning to technology stocks after assessing the impact of artificial intelligence on the software sector. The Dow Jones Industrial Average climbed 918 points, or about 2%, led by industrial stocks like Caterpillar (NYSE:CAT) and financial firms such as Goldman Sachs (NYSE:GS). The S&P 500 rose 1%, while the Nasdaq Composite added 1.5%. Despite the gains, both the S&P 500 and Nasdaq are still tracking lower for the week. Tech giants saw notable rebounds. Nvidia (NASDAQ:NVDA) surged 6%, recovering from steep losses earlier in the week. Microsoft (NASDAQ:MSFT) climbed 1%, while Amazon (NASDAQ:AMZN) fell 8% after reporting slightly weaker fourth-quarter earnings and announcing plans for $200 billion in capital expenditures in 2026. The software sector ETF, iShares Expanded Tech-Software (IGV), rose nearly 3% but remains down about 10% for the week. Barclays strategist Venu Krishna noted that AI concerns are being reassessed, and fundamentals for major tech companies remain resilient. Meanwhile, Bitcoin recovered 9% to above $69,000, after briefly dropping below $61,000. The CBOE Volatility Index (VIX) dipped below 20, signaling eased market jitters.
Wheat is trading with winter wheat contracts higher and spring wheat lower. The wheat complex posted gains across the three markets on Thursday. Chicago SRW futures closed 7 to 9 cents higher in the front months. Open interest was down 755 contracts on Thursday. KC HRW futures were 7 to 9 cents in the green on the day. OI dropped 1,963 contracts. MPLS spring wheat was up 4 to 6 cents at the close....
Wheat is trading with winter wheat contracts higher and spring wheat lower. The wheat complex posted gains across the three markets on Thursday. Chicago SRW futures closed 7 to 9 cents higher in the front months. Open interest was down 755 contracts on Thursday. KC HRW futures were 7 to 9 cents in the green on the day. OI dropped 1,963 contracts. MPLS spring wheat was up 4 to 6 cents at the close. Export Sales data from Thursday morning showed 373,877 MT of wheat sold in the week of January 29. That was down 33.02% from the previous week and 14.81% below the same week last year. The largest buyer was the Philippines, with 89,200 MT sold to Taiwan, and 67,900 MT to Mexico. Another 41,000 MT was sold for 2026/27. Don’t Miss a Day: Large world supplies continue to weigh on the market. Russia’s 2025 wheat crop totaled 93 MMT according to the country’s data, including Russian held territories of Ukraine. Area for 2026 is expected to total 83 MMT. Mar 26 CBOT Wheat closed at $5.35 1/4, up 8 1/2 cents, currently up 3 1/2 cents May 26 CBOT Wheat closed at $5.44, up 7 3/4 cents, currently up 3 1/4 cents Mar 26 KCBT Wheat closed at $5.38 1/2, up 8 1/4 cents, currently up 3 cents May 26 KCBT Wheat closed at $5.50 1/2, up 7 3/4 cents, currently up 3 cents Mar 26 MIAX Wheat closed at $5.72 1/2, up 5 1/2 cents, currently down 1 cent May 26 MIAX Wheat closed at $5.84 1/4, up 4 3/4 cents, currently down 1 cent On the date of publication, Austin Schroeder did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Phynart Studio/E+ via Getty Images TLDR: On January 29, 2026 Docebo Inc. ( DCBO ), a Canadian company listed in Canada and in the US, announced that the board of directors has approved a substantial issuer bid under which the company will offer to repurchase for cancellation up to US$60 Million worth of its outstanding common shares at a price of US$20.40 per common share. Over the last three trad...
Phynart Studio/E+ via Getty Images TLDR: On January 29, 2026 Docebo Inc. ( DCBO ), a Canadian company listed in Canada and in the US, announced that the board of directors has approved a substantial issuer bid under which the company will offer to repurchase for cancellation up to US$60 Million worth of its outstanding common shares at a price of US$20.40 per common share. Over the last three trading days (Tuesday February 3, Wednesday February 4, and Thursday February 5) the shares several times traded below $19.00. On Thursday February 5 (the most recent trading day before this article was written), the DCBO stock closed at $19.02, which is $1.38 lower than the Issuer Bid price (the "tender offer price") of $20.40. This allows you to buy shares at $19.02 and receive $20.40 for them when you tender them before the offer expires on March 10. What is a Substantial Issuer Bid? A Substantial Issuer Bid is the Canadian equivalent of what in the US is known as an Issuer’s Tender Offer. It is a stock repurchase mechanism where the company itself (the Issuer of the shares) sets a certain amount of funds aside for buying back its own shares at a set price and on a set date from its shareholders who agree to tender (submit) their shares into the offer. Unlike a Modified Dutch-Auction Tender offer, the offer price for the shares is fixed in advance so investors know upfront what price they will receive for their shares. This better visibility allows for a precise calculation of your potential profit with the only variable being the price at which you buy the shares. On occasion, while the tender offer is in progress, the market price of the stock drops significantly below the tender offer price, giving arbitrageurs the opportunity to purchase shares in the open market and then tender them (sell them to the company during the tender offer) at a price that is pre-set. This is exactly the opportunity we have here with the current price of DCBO. Please continue reading for the te...
The dollar is headed toward its first weekly gain since early January as turmoil in broader financial markets drove investors into havens and traders unwound bets against the currency that paid off when it tumbled. The Bloomberg Dollar Spot Index is up about 0.2% even after paring its gains Friday. The advance halted a three-week drop in the dollar that was fueled by speculation that the Trump adm...
The dollar is headed toward its first weekly gain since early January as turmoil in broader financial markets drove investors into havens and traders unwound bets against the currency that paid off when it tumbled. The Bloomberg Dollar Spot Index is up about 0.2% even after paring its gains Friday. The advance halted a three-week drop in the dollar that was fueled by speculation that the Trump administration’s policy shifts would spur foreign investors to dial back exposure to US assets. The reversal came as the stock market was whipsawed by volatility, Bitcoin tumbled and what had been a steep run-up in gold and silver prices abruptly reversed, all of which drove investors into the safety of US Treasuries. At the same time, analysts said investors started to take profits from widespread bets on the currency’s fall after bearish sentiment hit extreme levels late last month. “The market was heavily short USD as recently as last week, so there is likely a whiff of short-term profit taking here,” said Bipan Rai of BMO Asset Management. “That profit taking has been buttressed by decent US sentiment.” The gains were driven largely by the dollar’s advance against the yen ahead of Sunday’s national election in Japan, where polls show Prime Minister Sanae Takaichi ’s Liberal Democratic Party is expected to secure a big win. Hedge funds have increased bets against the yen, anticipating that a decisive mandate for Takaichi would allow her to enact fiscal-stimulus plans that could push up inflation. “The dollar firmed this week, largely reflecting yen weakness,” said Elias Haddad , global head of markets strategy at Brown Brothers Harriman. “Japan Prime Minister Sanae Takaichi’s expansive fiscal agenda is an ongoing drag for the yen as polls suggest her coalition is headed for a landslide victory.” The dollar’s advance came even as layoff and jobless-claims data this week pointed to further cooling in the labor market, which bolstered speculation that the Federal Reserve will ...
By Harshita Mary Varghese and Anhata Rooprai Feb 6 (Reuters) - U.S. tech giants have predicted their spending would surge this year as they double down on artificial intelligence, sharpening investor scrutiny over whether these costly bets would generate enough returns to justify the sector's high valuations. The group - including Alphabet, Microsoft, Amazon and Meta - is expected to pour more ...
By Harshita Mary Varghese and Anhata Rooprai Feb 6 (Reuters) - U.S. tech giants have predicted their spending would surge this year as they double down on artificial intelligence, sharpening investor scrutiny over whether these costly bets would generate enough returns to justify the sector's high valuations. The group - including Alphabet, Microsoft, Amazon and Meta - is expected to pour more than $630 billion combined largely into artificial intelligence this year, even as returns so far have lagged the pace of growth in the outlays. "Investors right now are not forgiving about large investments without clear signal on return on invested capital," analysts at Morgan Stanley said. Below is a snapshot of how the companies fared in the December quarter: CAPITAL EXPENDITURE Amazon.com, once seen as a laggard in the AI race, is leading the charge with $200 billion reserved in spending. Alphabet is close behind with as much as $185 billion, while Meta has projected up to $135 billion. CLOUD REVENUE Google Cloud notched the fastest growth among the three major U.S. cloud providers in the reported quarter with a rise of 48%. While the business is smaller than its major rivals, strong adoption of the latest Gemini model has led some analysts to say that Alphabet has taken the lead in the AI race. Amazon Web Services - the largest cloud player - meanwhile posted a revenue growth of 24%, while Microsoft's Azure reported a 39% increase. UNEVEN PROFIT Rising expenses weighed on profit growth at Amazon and Meta in the quarter, while Microsoft reported its strongest profit growth in two years. MARKET CAP GROWTH Optimism about Gemini and Google's deal to power Apple's revamped Siri have also boosted Alphabet's share price, which has in recent months far outperformed its rivals. (Reporting by Harshita Mary Varghese and Anhata Rooprai in Bengaluru; Editing by Sriraj Kalluvila)
hapabapa/iStock Editorial via Getty Images Compass ( COMP ) is said to have lost a bid to temporarily block a certain portion of Zillow's ( Z ) ( ZG ) listing ban policy, Bloomberg News reported on Friday, citing court records. The home listing platform reportedly has a policy that enables it to ban listings advertised elsewhere first. Compass's request for a preliminary halt on the policy was den...
hapabapa/iStock Editorial via Getty Images Compass ( COMP ) is said to have lost a bid to temporarily block a certain portion of Zillow's ( Z ) ( ZG ) listing ban policy, Bloomberg News reported on Friday, citing court records. The home listing platform reportedly has a policy that enables it to ban listings advertised elsewhere first. Compass's request for a preliminary halt on the policy was denied by the US District Judge Jeannette Vargas, the February 6 report noted. In June 2025, the largest brokerage in the U.S. by volume had sued Zillow, alleging that the latter and some of its allies are illegally steering all U.S. home listings to Zillow's platform so it can make money off each home listing "and protect its monopoly." Zillow can continue to block certain listings while the antitrust lawsuit proceeds, according to the news outlet. Compass was seeking to build a private listings network and encourage sellers to market properties with its agents before posting them on public platforms, Bloomberg noted. More on Compass, Zillow Compass: The Upside Opportunity Is Unsettling At This Price Level Compass: Strong Scale Advantage Zillow: Dominance May Be Crumbling (Rating Downgrade) Zillow Group downgraded at Mizuho amid market structure uncertainty Compass, Anywhere Real Estate avoided deal probe amid Justice Dept. rift - WSJ
Philippe TURPIN/Photononstop via Getty Images Matthews International ( MATW ) logged a decent quarter. The main takeaway for us is that the net debt figure we assumed from the proceeds of the SGK sale from before, the European packaging business and the warehouse automation business were similar to our target. While energy remains an uncertain end market, and EV growth basically plateaued with lim...
Philippe TURPIN/Photononstop via Getty Images Matthews International ( MATW ) logged a decent quarter. The main takeaway for us is that the net debt figure we assumed from the proceeds of the SGK sale from before, the European packaging business and the warehouse automation business were similar to our target. While energy remains an uncertain end market, and EV growth basically plateaued with limited interest in major capital outlays by upstream battery makers, we are at least looking forward to the inkjet printer solution which will hopefully have some traction in their markets. Unfortunately, compared to our previous understanding, we see that legal fees are continuing to drag on results and that the dispute with Tesla, despite Matthews prevailing initially in the courts on the patent issue, is ongoing ($7 million to $9 million from the same quarter last year). Nonetheless, with a more focused mix on the attractive memorialisation business, we are more confident in our SotP valuation as the possible multiples for the memorialisation business, backed by sponsor precedents, should become a more apparent source of mispricing of MATW stock in markets. It helps that capital markets are also in the process of reviving on lower inflation and capital costs. There's not so much more to do other than keep deleveraging, maybe find partners for the DBE business or ideally sell the major memorialisation business to private equity in a recovering sponsor environment. We are glad that an 18-24 month exit plan for Propelis has been communicated. Therefore, we aren't as worried about the lack of aggressive activism as of our last coverage . Results The net debt was $505 million which is quite close to our assumed target in the last coverage of $490 million based on the amount the company was supposed to receive from SGK, European Packaging business (Sauressig) and the warehouse automation business. They basically have no brand solutions business left, except for the part they sti...
"The staff stopped me as I walked in and were like 'we need to see your dog's ID'. Bobby was in harness, had the flash in her lead, was very obviously a guide dog, but they wouldn't let me go if I didn't have an ID for her.
"The staff stopped me as I walked in and were like 'we need to see your dog's ID'. Bobby was in harness, had the flash in her lead, was very obviously a guide dog, but they wouldn't let me go if I didn't have an ID for her.
Lindsay Corporation delivers irrigation and infrastructure solutions to global agriculture and transportation markets. On February 3, Pier Capital reported in an SEC filing that it sold out of Lindsay (LNN +1.71%), liquidating 71,799 shares in a transaction estimated at $10.09 million. What happened According to a Securities and Exchange Commission (SEC) filing dated February 3, Pier Capital fully...
Lindsay Corporation delivers irrigation and infrastructure solutions to global agriculture and transportation markets. On February 3, Pier Capital reported in an SEC filing that it sold out of Lindsay (LNN +1.71%), liquidating 71,799 shares in a transaction estimated at $10.09 million. What happened According to a Securities and Exchange Commission (SEC) filing dated February 3, Pier Capital fully exited its position in Lindsay (LNN +1.71%) by selling 71,799 shares. The estimated transaction value was $10.09 million. What else to know The Lindsay stake represented approximately 1.58% of AUM in the previous quarter and is now zero Top holdings at quarter-end: NYSE:MIR: $16.80 million (2.7% of AUM) NYSE:CWAN: $16.45 million (2.6% of AUM) NYSE:HXL: $11.99 million (1.9% of AUM) NASDAQ:ALHC: $10.80 million (1.7% of AUM) NASDAQ:FULT: $10.50 million (1.7% of AUM) As of February 2, Lindsay shares were priced at $127.27, down 1.86% over the past year and underperforming the S&P 500’s roughly 14% gain in the same period. Company overview Metric Value Revenue (TTM) $665.90 million Net income (TTM) $73.41 million Dividend yield 1.1% Price (as of February 2) $127.27 Company snapshot Lindsay offers irrigation systems, controls, and infrastructure solutions for water management and road safety, including the Zimmatic, Perrot, Greenfield, and GrowSmart brands. The company generates revenue by manufacturing and selling agricultural irrigation equipment and infrastructure products, as well as providing related technology and services. It serves agricultural producers, departments of transportation, municipal agencies, roadway contractors, and distributors in the United States and internationally. Lindsay is a leading provider of water management and road infrastructure solutions, operating at scale with a diversified product portfolio and global reach. The company’s strategy focuses on leveraging technology and engineering expertise to address critical needs in agricultural productiv...
Nvidia Corp. ’s Jensen Huang finally got what he spent months lobbying for when the US government authorized the company to sell its workhorse artificial intelligence chip to China. The Nvidia chief executive has argued that export controls imposed by Washington to limit Chinese access to his company’s most cutting-edge AI accelerators were depriving American companies of a lucrative and strategic...
Nvidia Corp. ’s Jensen Huang finally got what he spent months lobbying for when the US government authorized the company to sell its workhorse artificial intelligence chip to China. The Nvidia chief executive has argued that export controls imposed by Washington to limit Chinese access to his company’s most cutting-edge AI accelerators were depriving American companies of a lucrative and strategic foothold in the world’s biggest chip market. Relaxing the restrictions to allow Nvidia to sell the H200 AI accelerator there has given it a chance to grab a piece of the action and helped to sustain its position as the world’s most valuable company. But Huang will need to tread carefully. Suspicion of China runs deep in Washington, which could quickly reinstate the H200 ban if it emerges that the Beijing government is using the powerful chip for military purposes — or if US President Donald Trump simply changes his mind. The government in Beijing will also scrutinize every sale and could block shipments or ask Chinese companies to justify the purchases. Why was Nvidia locked out of China? Citing national security concerns, Washington limited the export of high-performance semiconductors to China during Trump’s first presidency, a policy that was upheld by his successor Joe Biden and tightened again when Trump returned to the White House. Policymakers still worry the same chips that power AI services such as ChatGPT and Claude risk accelerating the development of China’s nuclear weapon systems, military intelligence and cyberwarfare capabilities. US export license requirements have effectively blocked Nvidia and US rival Advanced Micro Devices Inc. from supplying their best products to Chinese customers. The two California-based companies lead the market for AI accelerators — the chips that create and then run AI software. Both tried to offer China-only versions of their product lines. These parts are less capable and are designed not to trigger the rules. Even these offeri...
Richard Drury/DigitalVision via Getty Images The Invesco QQQ Trust ETF ( QQQ ) has appreciated by only ~2.5% on a total-return basis since October 2025, outperformed by the JPMorgan Nasdaq Equity Premium Income ETF ( JEPQ ), which has gained ~6.5% in the same period. While this recent outperformance is noteworthy, I don’t believe that it’ll continue in 2026. In fact, I expect the QQQ to break out ...
Richard Drury/DigitalVision via Getty Images The Invesco QQQ Trust ETF ( QQQ ) has appreciated by only ~2.5% on a total-return basis since October 2025, outperformed by the JPMorgan Nasdaq Equity Premium Income ETF ( JEPQ ), which has gained ~6.5% in the same period. While this recent outperformance is noteworthy, I don’t believe that it’ll continue in 2026. In fact, I expect the QQQ to break out in the coming weeks as U.S. technology corporations announce their Q4 FY2026 results. In this highly probable scenario, it doesn’t make financial sense, from an opportunity cost perspective, to maintain a position in JEPQ - even if you’re someone who depends on it for income. Readers may assert that JEPQ leads to better downside protection, and they would be right to do so. Not only that, JEPQ also has a higher Sharpe ratio than the QQQ. But I’ll argue that the advantage will diminish in the coming months and years. Important Note If you are interested in an analysis of QQQ only, you may skip all sections of this article except those titled Extinguishing Headwinds , Not Even Close to a Bubble, and Closing Thoughts. Isn’t This Apples-to-Oranges? According to JEPQ’s website : JPMorgan Nasdaq Equity Premium Income ETF seeks to deliver monthly distributable income and Nasdaq 100 exposure with less volatility. That definition explicitly implies that JEPQ’s underlying portfolio mimics the QQQ, with income and lower risk as add-ons. Colloquially speaking, JEPQ purports that it has built a better mousetrap, and if it is better, it should provide higher total returns and better risk-adjusted returns. If it fails to do either or both and charges more, which it does with an expense ratio of 0.35% compared to 0.18% charged by QQQ, then investors are literally paying for nothing. Succinctly, JEPQ’s first litmus test should be a performance comparison against the QQQ, i.e., the baseline standard it must beat to justify its higher fee and its entire “better mousetrap” claim. More Money in...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Verisign Inc (Symbol: VRSN) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $249.75 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 56.7. A bullish investor could look at VRSN's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of VRSN shares: Looking at the chart above, VRSN's low point in its 52 week range is $175.62 per share, with $310.60 as the 52 week high point — that compares with a last trade of $251.66. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Molina Healthcare Inc (Symbol: MOH) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $297.90 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 43.3. A bullish investor could look at MOH's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of MOH shares: Looking at the chart above, MOH's low point in its 52 week range is $249.78 per share, with $374 as the 52 week high point — that compares with a last trade of $299.46. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Marzetti Co (Symbol: MZTI) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $153.06 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 50.5. A bullish investor could look at MZTI's 29.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of MZTI shares: Looking at the chart above, MZTI's low point in its 52 week range is $152.945 per share, with $198.39 as the 52 week high point — that compares with a last trade of $153.10. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Amazon.com Inc (Symbol: AMZN) entered into oversold territory, hitting an RSI reading of 27.2, after changing hands as low as $200.31 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 50.5. A bullish investor could look at AMZN's 27.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of AMZN shares: Looking at the chart above, AMZN's low point in its 52 week range is $161.38 per share, with $258.60 as the 52 week high point — that compares with a last trade of $205.47. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trad...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Illumina Inc (Symbol: ILMN) entered into oversold territory, hitting an RSI reading of 28.2, after changing hands as low as $119.48 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 50.5. A bullish investor could look at ILMN's 28.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ILMN shares: Looking at the chart above, ILMN's low point in its 52 week range is $68.70 per share, with $155.529 as the 52 week high point — that compares with a last trade of $120.22. Find out what 9 other oversold stocks you need to know about » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.